- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01949363
The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study
January 15, 2019 updated by: National Institute of Allergy and Infectious Diseases (NIAID)
The Pharmacokinetics of Extended Duration High-Dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study
This study is a Phase I, open label, non-randomized, dose-frequency escalation pharmacokinetics study among 24 healthy male and female subjects, aged 18 to 45 years to determine the pharmacokinetics and safety of high-, multi-dose cefixime for the treatment of reduced susceptibility gonorrhea.
Stage 1(Cohorts A and B) will examine the pharmacokinetics of single 400mg and 800mg dose of cefixime.
Stage 2(Cohorts C and D) subjects will take 800mg of cefixime every 12 hours for 2 doses.
If that dosing regimen is well tolerated, the dose-frequency will escalate to 800mg every 8 hours for 3 doses, and serum levels of cefixime will be measured.
Study duration is approximately 47 weeks.
Study Overview
Detailed Description
This study is a Phase I, open label, non-randomized, dose-frequency escalation pharmacokinetics study among 24 healthy male and female subjects, aged 18 to 45 years to determine the pharmacokinetics and safety of high multi-dose cefixime for the treatment of reduced susceptibility gonorrhea.
The study will occur in two stages as described below.
Stage 1: Confirm/establish the pharmacokinetics (PK) of 400mg and 800mg doses of cefixime tablet.
Stage 2: Define dosing frequency necessary to achieve total serum cefixime levels that exceed 2.0 mcg/mL for over 20 hours.
Stage 1 (Cohorts A and B): Six subjects will be admitted to the Johns Hopkins Bayview Clinic Trials Unit to assess each dosing regimen, for a total of 12 subjects.
At time=0, subjects will undergo baseline serum cefixime levels, followed by ingestion of cefixime.
Serum collections will occur at times 0, 1, 2, 4, 8, 12, 16, 20, and 24 hours.
Cohort B will have the same serum collection time points as Cohort A. Cohorts A & B will be run nearly simultaneously as logistically feasible.
Stage 2 (Cohorts C and D): After determining the PK parameters of single dose 800mg, the PK simulation model will be repeated, adjusting the model as needed based on findings from study Stage 1. Assuming there are no major discrepancies between Figure 2 (above) and the new PK simulations, the following regimens will be tested, beginning with Cohort C. Six subjects per dosing regimen, Cohorts C and D, will be admitted to the Johns Hopkins Bayview Medical Center, for a total of 12 subjects.
The 800mg q12 hour x 2 regimen (Cohort C) will be tested first.
For Cohort C, serum cefixime levels will be drawn at 12, 16, and 26 hours.
If the q12 regimen is deemed safe and tolerable after review by the SMC, Cohort D will commence with the 800mg q8 hour x 3 regimen.
Total serum cefixime levels will be drawn for Cohort D at 8, 16, 20 and 26 hours (see Section 7.2).
All Stages, All Cohorts: All samples collected for PK analysis will be shipped to the University of Toledo, Dr. Jeffrey Blumer's HPLC lab for processing.
Specimens will be analyzed by high performance liquid chromatography (HPLC) for total cefixime concentration levels.
Targeted clinical evaluations will be used to monitor for subject reported side effects.
Subjects will be asked about specific symptoms they may have experienced, including abdominal pain, nausea, vomiting, diarrhea, flatulence, headache, and rash, or any other symptoms.
Additionally, subjects will be asked to maintain a Subject Diary (Appendix E) from Study Day 0 through Day 7 to record information about any symptoms experienced or medications taken.
Study duration is approximately 47 weeks.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224-2735
- Johns Hopkins Bayview Medical Center - Infectious Diseases
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male or female subjects between 18 and 45 years, inclusive
- Ability to understand the consent process and procedures
- Informed consent obtained and signed
- Body mass index (BMI) < 35 kg/m^2
- Subjects agree to be available for all study visits
- Negative Breathalyzer
- Agreement by female subjects with reproductive potential to use an adequate method of contraception during the study and for 30 days after study drug administration. Female subjects must agree to the use of TWO reliable methods of contraception while receiving study drug and for 30 days after study drug administration if sexually active, which can include: condoms, spermicidal gel, diaphragm, hormonal or non-hormonal intrauterine device, surgical sterilization, oral contraceptive pill (OCP), and depot progesterone injections.
Exclusion Criteria:
- Subjects who take any prescription medication on a regular basis (except oral contraceptives, OCPs), including but not limited to, anti-psychotics, anti-depressants, anti-epileptics, cardiac medications, anti-hypertensives etc.
- Medical condition that precludes participation, including the following:
- Hypertension with confirmed systolic blood pressure >140 mmHg or confirmed diastolic blood pressure >90 mmHg, measured after 10 - 15 minutes of rest
- Morbid obesity (BMI>/=35)
- Current diagnosis of pulmonary disease
- History of or current diagnosis of diabetes
- Autoimmune disorder, such as lupus, Wegener's, rheumatoid arthritis
- History of malignancy except low-grade skin cancer, (i.e., basal cell carcinoma thought to be cured)
- Known diagnosis of prolonged QT interval
- History of alcohol abuse
- History of seizure disorder
- History of renal disease
- Chronic renal, hepatic, or pulmonary disease or other condition that could interfere with the absorption of the study drug or predispose to adverse gastrointestinal events (e.g., surgical resection of significant proportions of the stomach or bowel, gastric bypass, gastric banding, irritable bowel syndrome, inflammatory bowel disease)
- Positive serology results for HIV, HBsAg, or HCV antibodies
- Subjects who have taken any prescription drugs in the previous 14 days or within 5 half-lives before dosing
- Ingestion of over the counter medications or herbal supplements within 7 days of dosing
- Positive urine toxicology for marijuana, cocaine, amphetamines, opiates, PCP, barbiturates or benzodiazepines
- History of allergic reaction or intolerance to cephalosporins
- History of allergic reaction to penicillin (all stages)
- Subjects with an allergy to macrolides may not participate in Stage 3
- Subjects with QTc >450ms (Fridericia's correction) on screening ECG may not participate in Stage 3.
- Positive pregnancy test; pregnant or nursing women
- Screening laboratory tests outside of the acceptable limits presented in Appendix C
- Any specific condition that, in the judgment of the Investigator, precludes participation because it could affect subject safety
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stage 2 (Cohorts C and D)
Cohort C will first be given 1200mg cefixime orally once; Cohort D will be given 800mg cefixime orally three times (every 8 hours); 6 subjects in each cohort
|
Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic.
The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method.
Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
|
Experimental: Stage 1 (Cohorts A and B)
Cohort A will be given 400mg of cefixime orally once; Cohort B will be given 800mg of cefixime given orally once; 6 subjects in each cohort
|
Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic.
The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method.
Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total serum concentrations of cefixime at multiple time points for both individuals and cohorts in total
Time Frame: Day 1, 2 and Day 7
|
Day 1, 2 and Day 7
|
Safety and tolerability assessed by laboratory monitoring, targeted clinical evaluations,: serum chemistries, liver functions tests (LFTs), hematology panel, coagulation panel, and urinalysis
Time Frame: Screening to Day 7
|
Screening to Day 7
|
Pharmacokinetic curves of cefixime levels versus time: time to peak drug level, half-life, and elimination rate
Time Frame: Day 0-1, 2 and Day 7
|
Day 0-1, 2 and Day 7
|
Pharmacokinetic curves of cefixime levels versus time: total time that cefixime levels exceed 4x the MIC of 0.5 mcg/mL(serum level of 2.0 mcg/mL)
Time Frame: Day 0-1, 2 and Day 7
|
Day 0-1, 2 and Day 7
|
Pharmacokinetic curves of cefixime levels versus time: total area under the curve (AUC)
Time Frame: Day 0-1, 2 and Day 7
|
Day 0-1, 2 and Day 7
|
Pharmacokinetic curves of cefixime levels versus time: peak cefixime level.
Time Frame: Day 0-1, 2 and Day 7
|
Day 0-1, 2 and Day 7
|
Pharyngeal fluid concentrations of cefixime for Cohorts C - D: Cmax and ratio of fluid to serum concentration
Time Frame: Day 0-1
|
Day 0-1
|
Assess subject reported adverse events, unsolicited symptoms and discomforts
Time Frame: Up to Day 30
|
Up to Day 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (Actual)
February 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
September 19, 2013
First Submitted That Met QC Criteria
September 19, 2013
First Posted (Estimate)
September 24, 2013
Study Record Updates
Last Update Posted (Actual)
January 17, 2019
Last Update Submitted That Met QC Criteria
January 15, 2019
Last Verified
June 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-0025
- HHSN272201500007I
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gonorrhoea
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedGonorrhoeaUnited States
-
University of BernCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...TerminatedGonorrhoea | Trichomoniasis | Chlamydial InfectionUnited States
-
University of California, Los AngelesUniversity of California, San Francisco; NGO Via LibreCompletedHIV Infections | Gonorrhoea of Rectum | Chlamydia of RectumPeru
Clinical Trials on Cefixime
-
GlaxoSmithKlineWithdrawn
-
Tata Memorial HospitalUnknownCervical Inflammation and Human Papilloma Virus PerformanceIndia
-
Sheba Medical CenterUnknown
-
PT BernofarmPT Pharma Metric LabsCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of Southern CaliforniaUniversidad Peruana Cayetano Heredia; AIDS Healthcare FoundationRecruiting
-
Oxford University Clinical Research Unit, VietnamMedical Research Council; University of Oxford; Wellcome Trust; Department for...Recruiting
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Haiphong University of Medicine and PharmacyCompletedChlamydia Trachomatis Infection | Neisseria Gonorrhoeae InfectionVietnam
-
Children's Hospital Los AngelesNational Cancer Institute (NCI)CompletedDiarrhea | Neuroblastoma | Drug/Agent Toxicity by Tissue/OrganUnited States